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Abstract 
Cancer is a serious health issue in the world due to a large body of cancer-related human deaths, and there is no 
current treatment available to efficiently treat the disease as the tumor is often diagnosed at a serious stage. Moreo-
ver, Cancer cells are often resistant to chemotherapy, radiotherapy, and molecular-targeted therapy. Upon further 
knowledge of mechanisms of tumorigenesis, aggressiveness, metastasis, and resistance to treatments, it is neces-
sary to detect the disease at an earlier stage and for a better response to therapy. The hippo pathway possesses the 
unique capacity to lead to tumorigenesis. Mutations and altered expression of its core components (MST1/2, LATS1/2, 
YAP and TAZ) promote the migration, invasion, malignancy of cancer cells. The biological significance and deregula-
tion of it have received a large body of interests in the past few years. Further understanding of hippo pathway will be 
responsible for cancer treatment. In this review, we try to discover the function of hippo pathway in different diversity 
of cancers, and discuss how Hippo pathway contributes to other cellular signaling pathways. Also, we try to describe 
how microRNAs, circRNAs, and ZNFs regulate hippo pathway in the process of cancer. It is necessary to find new 
therapy strategies for cancer.
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Overview of the Hippo pathway
Hippo signaling pathway
Hippo signaling exerts a critical role in modulating cell 
proliferation and has been demonstrated to contribute to 
the progression of various diseases including cancer. The 
Hippo signaling pathway is primarily composed of mam-
malian Ste20-like kinases 1/2 (MST1/2) and large tumor 
suppressor 1/2 (LATS1/2), yes association protein (YAP) 
and/or its paralog TAZ (which is also known as WW 
domain containing transcription regulator 1 (WWTR1) 
[1]. Following the activation of the Hippo pathway, 
MST1/2 is phosphorylated and activates LATS1/2, which 
can then phosphorylate YAP/TAZ, resulting in the inhi-
bition of activity of YAP/TAZ. LATS kinases and its 
mammalian homologs MST1 and MST2 are activated by 
Hippo (Fig. 1) [1]. There are multiple functions of Hippo 
kinase activity associated with the activation of Hippo, 
including the promotion of MOB-Hippo or MOB-LATS 
binding, and the activation of LATS [2]. MOB proteins 
have diverse range of roles in the activity of LATS. The 
ability of MOB proteins to interact with Hippo and LATS 
kinases can result in the phosphorylation of LATS, and 
their associations with LATS induce a necessary confor-
mational change [3]. SAV was observed to link Hippo 
and Warts by acting as a scaffolding protein. In addi-
tion, SAV1 can inhibit the recruitment of SLMAP and 
maintain the activation of MST1/2 [4]. It has previously 
been reported that MST1/2 kinases can interact with the 
adaptor protein SAV and with phosphorylated LATS1/2 
kinase. The phosphorylation of LATS promotes their 
cytoplasmic localization in YAP proteins (Ser 127 of 
human YAP1, Ser 89 of human TAZ) by creating a bind-
ing site on 14-3-3 proteins [2]. In addition, previous stud-
ies have demonstrated that the expression of YAP/TAZ is 
unusually excessive in tumors, enhances the occurrence 
of tumors and is thought to be a cancer gene for a large 
number of solid cancers [5, 6].
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YAP proteins
Hippo signaling can influence cellular phenotypes by 
inhibiting the transcriptional co-activator protein Yki, 
or its mammalian homologs YAP and TAZ [7]. Several 
DNA-binding partners have been identified, which are 
essential for the activation of the YAP protein, as YAP 
lacks a DNA-binding domain. Of these partners, the 
primary ones are TEAD proteins, including TEAD 1–4 
of mammals, and Scalloped (Sd) of flies [8]. The WW 
domain has two highly conserved tryptophans, and has 
been hypothesized to modulate protein–protein interac-
tions, and the other WW domain is conserved in YAP 
across species. It has been reported that YAP1contains 
only one WW domain, whereas, YAP2 consists of two 
WW domains [1] (Fig.  2). A previous study performed 
a binding assay and observed that the WW domains 
can associate with PPXY motifs of WBP-1 and WBP-2 
[9]. Of note, YAP was identified to be a transcription 
co-activator containing a C-terminal transcription acti-
vation domain [10]. The four amino acids of the C-ter-
minal of YAP interact with PDZ domains in proteins, and 
may be important in regulating the subcellular localiza-
tion of YAP [11]. A recent study demonstrated that the 
YAP-TEAD heterodimer could interact with other tran-
scription factors involved in Taiman, GAGA, AP-1, and 
β-catenin, and contribute to the regulation of down-
stream genes [12].
The phosphorylation of YAP on Ser127 binds with the 
14-3-3 protein and inhibits its transcriptional activity via 
cytoplasmic sequestration. A phosphatase, such as pro-
tein phosphatase-1, can dephosphorylate YAP Ser127 
and enhance the nuclear accumulation and transcrip-
tion activity of YAP [13]. The phosphorylation of on YAP 
Ser381, can affect its stability and induce subsequent 
phosphorylation by casein kinase 1, and activate a phos-
phodegron degradation motif [14].
Growth promoting genes such as Myc, CycE and 
E2F1, which are cell cycle regulators, and Diap1 and 
Fig. 1 Hippo pathway Phosphorylated MOB recruits LATS (together 
with SAV and MST1/2). LATS is then phosphorylated by hippo to 
generate activated LATS, which can then phosphorylate YAP/TAZ and 
promote their cytoplasmic localization by creating a binding site for 
14-3-3 proteins. YAP/TAZ and TEAD, the heterodimer, can enhance 
cancer
Fig. 2 YAP protein and TAZ protein YAP protein is involved in YAP1 and YAP2 proteins. YAP1, it is involved in one WW domain, whereas, YAP2 
composes of two WW domains. TAZ isoform that is commonly studied possesses one WW domain. In contrast with YAP, TAZ lacks of p-rich and 
SH3-binding domains
Page 3 of 17Han  J Transl Med          (2019) 17:116 
BIRC3, which are inhibitors of apoptosis, contribute 
to the activation of YAP proteins, which is associated 
with an increase in tissue growth [15]. The ligands of 
the Wnt, Notch, EGFR, TGF-β, and JAK-STAT signal-
ing pathway have also been identified as targets of YAP 
proteins, which can regulate tissue growth [16]. In addi-
tion, a group of upstream components of the Hippo 
pathway, including Merlin, Ex, Kibra, Angiomotin-like 
2 (AMOTL2), and LATS kinases have been reported to 
serve an essential role in negatively coordinating YAP 
proteins [1].
TAZ protein
The structure of TAZ is also composed of two trypto-
phan residues [17]. The commonly observed human TAZ 
isoform possesses one WW domain (Fig.  2). TAZ also 
shares a C-terminal PDZ-binding motif, which mediates 
interactions with the 80–90 amino acid protein-inter-
action domains. PDZ domains [18] have been identified 
in several proteins, many of which are associated with 
trans-membrane or cytoskeleton. Additionally, a domain 
in the N-terminal region of TAZ mediates its bind-
ing to TEAD transcription factors. Although much of 
the TEAD-binding domain is conserved in TAZ, recent 
molecular modeling studies have confirmed differences 
in the combination of TAZ and YAP and TEAD tran-
scription factors, due to TAZ lacking the PxxΦP motif 
[19]. The TEAD-binding region in TAZ is in very close 
interaction with that required for 14-3-3 binding, which 
fosters cytoplasmic sequestration and is one of the major 
mechanisms through which the Hippo pathway controls 
TAZ/YAP localization and activity.
Although TAZ and YAP shared several identical fea-
tures, differences are evident. For example, the extreme 
N-terminus of YAP contains a proline-rich region; how-
ever, this has not been identified in TAZ. It has been 
reported that the proline-rich area interacts with the 
heterogeneous nuclear ribonuclear protein U (hnRNPU), 
which serves a role in mRNA processing [20]. YAP also 
possesses a SH3-binding motif (amino acids PVKQPP-
PLAP), which is lacking in TAZ. This region mediates 
interactions between the SH3 domains of several pro-
teins, including the YES and SRC kinases, as well as the 
adaptor proteins NCK and CRK [21]. Despite the afore-
mentioned examples, differences in the features of TAZ 
and YAP have not been the subject of much investigation, 
and require further study.
Signals of regulation of Hippo signaling
Hippo signaling can be modulated by various signals in 
cancer cells (Fig. 3), which exert a critical role in tumori-
genesis. Therefore, it is imperative to observe this signal-
ing network in order to improve the presently available 
understanding.
Wnt pathway
Overexpression of the Wnt pathway possesses frequent 
APC or β-catenin mutations, which is a key feature in 
human cancer. In terms of scaffolding proteins such 
as APC, Axin and DVL of canonical Wnt signaling can 
act as key intracellular regulators of β-catenin dynam-
ics [22]. An abundance of studies have concentrated on 
the role of YAP in Wnt suppression by DVL, through 
which YAP cannot tightly associate with Hippo and Wnt 
[23]. In addition, the scaffolding protein of DVL drives 
the nuclear export of the phosphorylation YAP. The 
DVL contains conserved nuclear export signals (NES, 
M/LxxLxL) located next to the DEP domain, with NES 
Fig. 3 Different pathways regulation of hippo pathway. Wnt pathway and AMPK pathway inhibit YAP protein. TAZ protein promotes TGF-β pathway. 
KRAS and MAPK/ERK promotes YAP protein
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being responsible for the cytoplasmic translocation of 
YAP. Importantly, the cytoplasmic translocation of YAP 
is induced by the close contact inhibition of E-cahderin, 
α-catenin or AMPK activation, which requires DVL. 
This indicates that the Wnt scaffold protein DVL exerts 
a key shuttle effect on the Hippo pathway. In summary, 
the function of the Wnt pathway is opposite to that of the 
YAP protein, which may provide the basis for an impor-
tant therapeutic strategy.
AMPK pathway
AMPK can act as a key cellular energy sensor to directly 
phosphorylate YAP at multiple sites, and as a primary 
cellular metabolism regulator to impair its activity. The 
hyper-expression of AMPK suppresses cell proliferation, 
and YAP and TAZ, both of which can result in the inhibi-
tion of AMPK-mediated growth [24]. In addition, AMPK 
may also indirectly phosphorylate AMOTL1, which can 
promote the activity of LATS as well inhibiting the activ-
ity of YAP and inducing YAP phosphorylation, further 
strengthening the AMPK-mediated inhibitory regulation 
on YAP [25]. Additionally, LKB1 has been demonstrated 
to inhibit Yki activity in an AMPK-dependent man-
ner in a Drosophila study, although other mechanisms 
were also observed in human cells [26]. Notably, cellular 
energy stress can inhibit YAP through AMPK-dependent 
and -independent mechanisms. In AMPK knockout cells, 
LATS kinase can be activated to cope with energy stress, 
suggesting that cell energy stress can also activate the 
hippo pathway through mechanisms unrelated to AMPK. 
Glucose starvation activating molecular basis of LATS is 
an interesting hypothesis that requires further investiga-
tion [27]. Based on these perspectives, the association 
between AMPK and YAP require further invesitgation.
TGF‑β pathways
The TGF-β signaling pathway participates in various 
cellular functions including cell proliferation, apopto-
sis, differentiation and remodeling of the extracellular 
matrix [28]. Previous studies have detailed the relation-
ship between TAZ/YAP and TGF-β through analyzing 
the levels of genes associated with intracellular signaling 
and transcriptional regulation [29]. TAZ binds to het-
eromeric Smad2/3-Smad4 complexes and is necessary 
for TGF-β response elements, resulting in maintaining 
the nuclear accumulation of the Smad2/3-Smad4 com-
plex and TGF-β mediated stem cell self-renewal [30]. 
The cytoplasmic retention of phosphorylated TAZ can 
prevent Smad2/Smad4 complexes from accumulating in 
the nucleus, while TAZ knockout can lead to TGF sig-
nal inhibition and neural epithelial differentiation [31]. 
Smad2/3, TEAD4, and TAZ/YAP form a complex with 
OCT4, which promotes the transcription of pluripotency 
genes while suppressing mesendodermal differentiation. 
Through the co-regulation of the Smad2/3-Smad4 com-
plex and FOXH1, the disruption of this complex was 
observed to promote the induction of mesendodermal 
genes. Therefore Smad2/3-mediated transcription seems 
to be a positive and negative regulator of interactions 
with TAZ/YAP in a context-dependent manner [29].
KRAS signaling
Recent observations have indicated that the overexpres-
sion of YAP1 dissociates K-Ras4B inhibition. Therefore, 
the transcriptional activation of YAP1 and β-catenin as 
a survival rescue strategy of K-Ras4B-inhibited cells [32, 
33] has further become a key concern, as it can negate 
the effects of K-Ras4B therapeutics. YAP1 and β-catenin 
transcriptional regulators serve a role in the targeting 
of K-Ras4B and can induce resistance by controlling the 
progression of cells from the G1 phase to S phase in the 
cell cycle. The role of ERK corresponds to that of YAP1 
and PI3Kα. ERK and YAP can produce consequences 
similar to those of PI3K and β-catenin, which is why 
K-Ras4B drug resistance is caused by the expropriation of 
YAP and β-catenin [32–34]. The emerging picture from 
relevant experimental and clinical data suggests that 
oncogenic KRAS, YAP1 and β -catenin serve similar roles 
in cell cycle control in tumor initiation [34].
MAPK/ERK signaling
Recent studies have reported that mutations in the 
Hippo signaling components SAV1, MST1/2 and Lats1/2 
are not evident in human cancer. Even if rendering this 
signaling, it can unlikely explain the vigorous activation 
of the YAP in the majority of; however, not all human 
tumors. An associated study has also demonstrated that 
an activated YAP promotes the resistance to MAPK/ERK 
Kinase (MEK)-targeted inhibitor therapy [35]. The sensi-
tivity of YAP elevated cancer cells to MEK inhibitors and 
the knockdown of this effect has been demonstrated in 
numerous types of cancer cells. Therefore, YAP activ-
ity predicts the therapeutic effect of MEK inhibitors in 
patients with cancer with activated MAPK signals. Addi-
tionally, previous studies have demonstrated in compara-
ble MAPK vs. YAP1 cell cycle actions, that the nucleotide 
sequences of the DNA response elements of the down-
stream transcription factor complexes modulated by 
these two cellular pathways are similar [36, 37].
Role of microRNAs on Hippo pathway in cancer
microRNAs
microRNAs (miRNAs) are a group of small regulatory 
RNAs that function in the 3′untranslated region (UTR) 
of a messenger RNA and guide post-transcription inhibi-
tion by binding in a sequence-specific manner [38]. The 
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biogenesis of miRNAs begins with the transcription of 
RNA polymerase II from the miRNA gene to the primary 
miRNA (pri-miRNA), which has been demonstrated to 
form a hairpin loop [39]. The end of the hairpin is then 
recognized and processed into a 60-nt stem-loop struc-
ture called a pre-miRNA by the endonuclease Drosha 
and DGCR8. The pre-miRNA is then exported out of the 
nucleus via Exportin 5 and RAN-GTP, where it is fur-
ther processed into the mature miRNA [40]. The mature 
miRNA is located to an Argonaute protein with assis-
tance from additional chaperone proteins in a complex 
known as the RNA-induced silencing complex (RISC) 
[41]. The RISC-associated miRNA is then guided by the 
“seed region” (nucleotides 2 to 8) to the complementary 
seed match” site of a target mRNA, resulting in the deg-
radation of mRNA [42]. Importantly, the seed area of 
any particular miRNA is expected to target thousands of 
mRNA, and each mRNA can have hundreds of miRNA 
seed matching sites in their 3′UTR [42]. Due to this 
broad regulatory potential, miRNAs are considered to be 
the largest type of gene regulator capable of “fine-tuning” 
gene expression, and influencing the pathogenesis/pro-
gression of a variety of diseases [43]. microRNAs can 
affect cancer through the hippo pathway, which was 
described below and summarized in Fig. 4 and Table 1.
microRNAs and Hippo pathway
miR‑550a‑3‑5p
Recent data has demonstrated that miR-550a-3-5p sup-
presses cell proliferation, metastasis, and tumor sphere 
formation through directly inhibiting oncogenic YAP 
in various types of cancer cells [44]. Additional stud-
ies have also demonstrated that miR-50a-3-5p-mediated 
YAP regulation has clinical correlations in a variety of 
cancers, including the inverse relationship between the 
signature of miR-50a-3-5p and YAP in colon cancer, and 
its prognostic value in esophageal cancer. Importantly, 
Choe et al. reported that treatment with miR-550a-3-5p 
improved the sensitivity of vemurafenib by inhibiting 
YAP, and reducing the activity of AKT in vemurafenib-
resistant colon cancer and melanoma cells [45].
Fig. 4 miRNAs and Hippo pathway. YAP/TAZ could inhibit the processing of pri-miRNA to pre-miRNA. Several miRNAs can make an effect on Hippo 
pathway
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miR‑665
Previous studies have demonstrated that the expression 
of mir-665 in hepotacelluar carcinoma (HCC) and tis-
sues is elevated [46]. The patients with HCC with a high 
expression of mir-665 exhibited more severe tumor 
size, vascular infiltration and Edmondson grading. 
Functional loss or gain tests have demonstrated that 
mir-665 promotes the proliferation, migration, invasion 
and epithelial-mesenchymal transition (EMT) of HCC 
cells in vitro and in vivo. Tyrosine phosphatase recep-
tor type B (PTPRB) was observed to be downregulated 
in HCC tissues, and was negatively correlated with 
miR-665 expression. The restoration of PTPRB reverses 
the effects of miR-665 on HCC migration and invasion. 
In addition, a mechanistic study clearly demonstrated 
that PTPTRB mediated the functional role of miR-665 
through regulation of the Hippo signaling pathway. In 
summary, modulating PTPRB expression reversed the 
effects of miR-665 on the Hippo signaling pathway [47].
miR‑195
miR-195 belongs to the miR-15 family. An increas-
ing amount of research has focused on the functions 
of miR-195 in tumorigenesis over the past few years. 
miR-195 is considered to function as a tumor inhibi-
tor in certain types of cancer [48, 49]. The study of Yu 
et al. demonstrated that the expression of miR-195 was 
markedly decreased in HCC, and its low expression 
level was closely associated with the poor clinical char-
acteristics in patients with HCC. Conversely, the level 
of YAP in HCC tissues is extremely high, and the level 
of YAP in metastatic tissue is equally high. In addition, 
a strong negative correlation was identified in HCC tis-
sues with low levels of miR-195 expression and high 
levels of YAP. Notably, this study confirmed that sig-
nificant predictors of prognosis can be used in patients 
with HCC, including miR-195, YAP and their combi-
nations, and mechanistically confirmed that miR-195 
inhibits the migration, invasion and EMT of HCC cells, 
which is related associated with the repression of YAP 
[50].
miR‑3910
miR-3910 has been observed to promote the growth of 
HCC cells on liquid culture and soft agar. In addition, 
miR-3910 is a positive regulator of cellular dynamics, as 
evidenced by a Boyden chamber assay and an intrahe-
patic metastasis assay. These observations clearly dem-
onstrated the carcinogenic effects of miR-3910 in HCC 
tumors. The application of YAP signal activation in the 
occurrence of HCC has been widely identified [51, 52]. 
The knockdown of MST1, MST2, and SAV has been 
demonstrated to induce tumor formation in the liver of 
mice [53], emphasizing the pivotal function of YAP sign-
aling in the initiation of HCC. The study of Cheng et al. 
identified that miR-3910 regulated the expression of 
MST1, saved the apoptosis induced by MST1, and con-
firmed that miR-3910 exerted a carcinogenic function 
with MST1 as the target [54].
miR‑874‑3p
The expression of miR-874-3p was significantly decreased 
in colorectal carcinoma (CRC) tissues compared with 
adjacent normal tissues. It has also been observed that 
the upregulation of miR-874-3p increased the apopto-
sis ratio and decreased the mitochondrial potential of 
CRC cells with 5-FU treatment in  vitro, and reduced 
the chemoresistance of CRC cells to 5-FU in  vivo. By 
contrast, the knockdown of miR-874-3p decreased the 
apoptosis ratio and increased the mitochondrial potential 
of CRC cells following treatment with 5-FU treatment 
in vitro and enhanced the chemo-resistance of CRC cells 
to 5-FU treatment in vivo. Que et al. demonstrated that 
miR-874-3p directly inhibited YAP and TAZ, leading to 
the inactivation of TEAD transcription and the down-
regulation of Hippo downstream target genes, such as 
CTGF, BCL2L1 and cyclin A [55].
Table 1 microRNAs in cancers
microRNAs Function Cancer Mechanism References
miR-550a-3-5p Suppressed cell proliferation, metastasis, and tumor sphere 
formation
Colon, 
esophageal,melanoma
Inhibiting YAP [45]
miR-665 Promoted cell proliferation, migration, invasion, and the 
epithelial–mesenchymal transition
Hepotacellular Inhibiting hippo pathway [47]
miR-195 Inhibited the migration, invasion and epithelial–mesenchy-
mal transition
Gastric, breast, thyroid and 
hepotacellular
Suppressing YAP [50]
miR-3910 Inhibited apoptosis induced the tumor formation Hepotacellular Suppressing MST1 [53, 54]
miR-874-3p Increased the apoptosis ratio and decreased the mitochon-
drial potential
Colorectal Inhibited YAP and TAZ [55]
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Role of circular RNAs on Hippo pathway in cancer
circRNAs
circRNAs have originally been considered as non-func-
tional accidental by-products of aberrant splicing [56], 
and to a certain extent, have been the focus of numer-
ous studies. Due to the emergence of next-generation 
sequencing techniques, a large number of circRNAs 
have been identified to be widely expressed in eukaryotic 
cells. circRNA is a single-chain transcription obtained 
from exons, introns, or intergenic regions, which have 
covalently closed continuous loops, display cell or tissue 
specific expression, and remains constant between spe-
cies due to resistance to RNase R [57]. Due to the closed 
structure, circRNAs have been observed to be highly sta-
ble. Numerous circRNAs exhibit evolutionary conserva-
tion, and the expression spectrum is unique to the cell 
type or stage of development [58]. The function of circR-
NAs on the Hippo pathway iss summarized in Table 2.
circular RNAs and Hippo pathway
circ_104075
The expression of circ_104075 was observed to be mark-
edly elevated in HCC tissues, cell lines and serum. cir-
cRNA can act as a competing endogenous RNA (ceRNA) 
to absorb microRNA, and indirectly stimulate protein 
expression. circ_104075 can also upregulate the expres-
sion of YAP by absorbing miR-582-3p by acting as a 
ceRNA. Of note, an  N6-methyladenosine  (m6A) motif 
was identified in the 353-357 region of YAP 3′UTR, 
which was revealed to be essential for interactions 
between miR-582-3p and YAP 3′UTR. In addition, recent 
study has demonstrated that circ_104075 can be used for 
diagnosis [59]. In summary, circ_104075 may serve as a 
potential target for the diagnosis and treatment of HCC.
hsa_circ_0023404
circRNA hsa_circ_0023404 was significantly upregulated 
in CC tissues when compared with adjacent normal tis-
sues, which was indicative of a poor prognosis in patients 
with CC. Functionally, the knockdown hsa_circ_0023404 
significantly suppressed the proliferation, arrested cell-
cycle progression and inhibited cell migration and inva-
sion in CC. Mechanistically, hsa_circ_0023404 acted as a 
sponge of miR-136, which is an activator of the YAP sign-
aling pathway. Additionally, hsa_circ_0023404 activated 
the YAP pathway in CC via promoting the expression of 
TFCP2 by sponging miR-136, leading to the development 
and progression of CC [60].
circPVT1
Memczak et  al. first identified CircPVT1 as circ6 [61] 
and then named circPVT1 after its host gene, PVT1, 
which was analyzed in subsequent studies [62, 63]. The 
PVT1 gene is highly expressed in numerous types of can-
cers, such as head and neck squamous cell carcinoma 
(HNSCC) [64]. The circPVT1 locus is in the long non-
coding RNA PVT1, and it originates from exon 2 of the 
PVT1 gene (human genome GRch38/hg38). circPVT1 is 
highly expressed in tumors compared with non-tumor 
tissues, especially in patients with TP53 mutations. YAP 
can regulate circPVT1 at the post-transcriptional level, 
and following YAP knockdown, the binding to circPVT1 
was lost. In addition, YAP did not bind circPVT1 as a 
results of the downregulation of of mut-p53 [65].
circLARP4
circLARP4 exhibits the potential to sponge miR-424, and 
recent studies have demonstrated that LARP4 inhibits 
cancer cell migration and invasion via a La-related RNA-
binding protein [66]. The study of Zhang et al. reported 
that circLARP4 was differentially-expressed between GC 
and adjacent normal tissues, and was derived from Exon 
9, 10 of the LARP4 gene and intermediate long intron. 
Further functional experiments have demonstrated that 
the excessive expression of peripheral LARP4 inhib-
its the synthesis of DNA, cell proliferation and invasion 
by sponging miR-424 and regulating of the expression 
of LATS1 and YAP genes. circLARP4 revived LATS1 
and p-YAP expression, decreased the expression of 
YAP, restored the expression of LAST1 and p-YAP, and 
Table 2 Circular RNAs in cancers
Circular RNAs Function Cancer Mechanism References
circ_104075 Promoted cancer growth Hepatocellular Up-regulate YAP expression [59]
hsa_circ_0023404 Promoted the proliferation and promoted 
the cell-cycle progression suppressed cell 
migration and invasion
Colorectal Activated YAP pathway in CC via promoting 
TFCP2 expression by sponging miR-136
[60]
circPVT1 An increase of the malignant phenotype Head and neck 
squamous cell 
carcinoma
Binding to YAP [64, 65]
circLARP4 Inhibits cancer cell migration and invasion Gastric Regulation of miR-424/LATS1/YAP signaling 
pathway
[66, 67]
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reduced YAP expression, as well as offset the impact of 
miR-424., suggesting that circLARP4 may function as a 
tumor suppressive factor in GC via regulation of the miR-
424/LATS1/YAP signaling pathway [67].
Role of ZNFs on Hippo pathway in cancer
ZNFs
The first zinc finger (ZNF) was transcriptional fac-
tor (TFIIIa) of Xenopus laevis [68]. ZNFs are classified 
based on the zinc-finger domain structure. Relevant 
research has revealed that there are eight different types 
of zinc finger motifs including  Cys2His2  (C2H2) like, Gag 
knuckle, Treble clef, zinc ribbon,  Zn2/Cys6, TAZ2 domain 
like, zinc binding loops as well as Metallothionein [69].
The motifs of amino acid residues form mononuclear 
Zn-binding sites such as  ZnHis2Cys2,  ZnHisCys3, and 
 ZnCys4. The most commonly identified motifs include 
 C2H2-type, treble clef, and zinc ribbon. RING finger pro-
teins, contain  Zn3His and  ZnCys4 sites and serve a piv-
otal function in the process of ubiquitination, and are 
unique [70, 71]. The monograph describes in detail the 
zinc finger (Zf ) pattern that binds to DNA, RNA, pro-
teins, and small molecules and considered to be impor-
tant Zf domains. A shift of the central zinc ion combined 
with the coordination of mutations in amino acids can 
lead to the loss of ZFS biological function, a process that 
can be used to inhibit the activity of ZFS in processes that 
are dangerous to the human body, especially the occur-
rence of tumors [72]. Therefore, Zf ZF can be used as a 
bio-target, which is affected by the purpose of destroying 
conformation control of the role of zinc. This causes it to 
be released and triggers a functional interruption in pro-
cesses like transcription.
Recent findings have highlighted the importance of 
ZNFs in the onset and progression of cancer through 
regulating the Hippo pathway. ZNFs are involved in all 
the principal pathways in which cancer is formed rang-
ing from carcinogenesis to metastasis. Additionally, 
ZNFs are involved in cancer via their transcription factor 
function. In addition, emerging evidence suggested the 
importance of the ZNF protein as a chromatin modifier 
or as a structural protein that regulates the migration and 
invasion of cancer cells.
Transcription factors serve a central role in regulat-
ing gene expression and mediating a set of biologi-
cal processes, including differentiation, development, 
metabolism, apoptosis, autologous phagocytosis and the 
maintenance of stem cells [73]. According to different 
DNA binding patterns, transcription factors are mainly 
divided into classical zinc fingers, homeodomains and a 
basic helix-loop-helix. Among these, classical zinc finger 
containing proteins (ZNFs) are composed of the larg-
est sequence of specific DNA binding protein families, 
encoded by 2% of the human gene [74]. Previous stud-
ies exhibit different regulatory mechanisms on a variety 
of downstream genes by recruiting different chromatin 
modifiers. Specific ZNF proteins are used as transcrip-
tion inhibitors by recruiting co-pressure proteins [75]. 
We subsequently described several ZNF proteins in order 
to evaluate whether they can regulate the hippo pathway 
and effect the progression of tumors (Fig. 5).
ZNFs and Hippo pathway
MZF1
myeloid zinc finger 1 (MZF1) has been observed to be 
elevated in several cancers, and its excessive expres-
sion inhibits apoptosis and promotes the occurrence 
of tumors [76], while the silencing of MZF1 leads to 
reduced tumor growth. Recent data has indicated that 
MZF1 is essential for the transcription of basal YAP1, 
and promotes tumor formation through stimulating the 
expression of YAP1. The factor is highly expressed in 
osteosarcomas (Oss) and binds to distinct sites in the 
YAP1 enhancer. Depletion of this factor leads to a dras-
tically reduced YAP1 expression and therefore reverses 
stem cell properties, as well as producing an opposing 
effect via downregulating the expression of YAP1, which 
decreases the stem cell fraction and restores osteogenic 
differentiation [77].
ZFP226
ZFP226 belongs to the  Cys2–His2 zinc finger type and 
recognizes a nine base pair DNA sequence 5′-GGC-
GGC-GGC-3′ in the well-characterized KIBRA core pro-
moter P1a [78]. This DNA target sequence was selected 
due to its position in a highly sensitive transcription 
active region, which is highly sensitive to promoter meth-
ylation [79]. Previous studies have observed a significant 
increase in the relative levels of plats 1, and importantly 
in p-YAP in IHKE cells at 48 h following ZFP226 trans-
fection [78]. Of Note, YAP expression was unaffected by 
pZFP226 transfection [80]. Most importantly, the study 
of Schelleckes et  al. reported that ZFP226 was able to 
induce apoptosis by activating hippo signaling in human 
breast adenocarcinoma cells following transfection with 
ZPF226.
ZEB1
The zinc finger E-box-binding homebox (ZEB) family 
includes ZEB1 and ZEB2, which are important nuclear 
transcription factors and have been reported to be key 
factors in EMT [81]. Mechanistically, ZEB1 can sup-
press epithelial genes that can stimulate an undifferen-
tiated and highly motile phenotype as a transcriptional 
repressor [82]. This property of ZEB1 is considered to 
exert an important role in metastasis, and this has been 
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demonstrated in numerous types of model systems. 
Lehmann et  al. reported that ZEB1 can directly inter-
act with YAP, which can render ZEB1 from a repressor 
to a transcriptional activator, and thereby act as a similar 
cancer-promoting effect. In addition, functional coopera-
tion between ZEB1 and YAP is a useful predictor of poor 
survival, and significantly increases the metastatic risk in 
hormone receptor-negative breast cancer [83].
CIZ1
Previous studies have demonstrated that Cip1 activated 
YAP signaling in HCC cells through interactions with 
zinc finger protein 1 (CIZ1), and also induced the growth 
and migration of cancer cells. The study Liu et al. dem-
onstrated that CIZ1 interacted with the transcriptional 
factor YAP in HCC cells. CIZ1 can interact with YAP 
due to its nuclear matrix anchor domain, and CIZ1 also 
enhanced the YAP to interact with TEAD. Additionally, 
knocking down CIZ1 decreased the transcriptional activ-
ity as well as the biological functions of YAP. Based on 
these discoveries, CIZ1 is a positive regulator of YAP 
signaling, and may serve as a therapeutic strategy for 
HCC [84].
Function of Hippo pathway in cancers
Hippo pathway in carcinoma
NSCLC
In non-small cell lung cancer (NSCLC), the overexpres-
sion of YAP is associated with the development, progres-
sion and poor prognosis of diseases, and the TAZ exerts a 
similar function. An epidemiological study demonstrated 
that a mutation of YAP, which causes carcinogenicity 
hyperactivity, is associated with the occurrence of lung 
cancer [85]. In  vivo studies in lung adenocarcinoma 
mouse models have revealed that the genetic loss of YAP 
reduces the number of experimentally induced tumor 
masses in mice [86, 87].
The increase in the nuclear activity of YAP and TAZ 
may be caused by an increase in signals, receptors or 
sensors that actively regulate YAP/TAZ activity, or a 
decrease in signals or molecules that negatively regulate 
the carcinogenic function of YAP/TAZ [88]. For example, 
oncogenic ABL1 and 2 kinases have been observed to be 
Fig. 5 The relationship between zinc finger proteins and hippo pathway in cancers. MZF1 promote osteosarcomas through stimulation of YAP1 
expression. ZFP226 was able to induce apoptosis by activating hippo signaling in human breast adenocarcinoma. Cooperation of ZEB1 and YAP 
stimulates and increases risk in breast cancer. CIZ1 interacted with the transcriptional factor YAP in hepatocellular carcinoma and enhanced cancer 
growth
Page 10 of 17Han  J Transl Med          (2019) 17:116 
overexpressed or hyperactivated in NSCLC [89, 90] and 
are also involved in the tumor growth and metastasis of 
lung cancer experimental models, which have recently 
been demonstrated to be regulated to some extent, via 
the role of TAZ and β-catenin by inhibiting their binding Β-TRCP, which increases their stability [88].
In addition, LATS2 is downregulated in 60% of NSCLC 
cancers, and its high levels led to an improved prognosis 
and negative regulation of carcinogenic YAP in NSCLC 
[91]. In addition, MST1 kinase has been demonstrated 
to inhibit the growth of NSCLC in vitro and in vivo [92]. 
Notably, Ras-association domain family 1 isoform A 
(RASSF1A) activates MST1/2 and LATS1 in the presence 
of DNA damage or other stress signals in NSCLC [93].
Breast cancer
An abnormal Hippo pathway facilitates breast can-
cer metastasis through different mechanisms [94]. The 
Hippo core components such as YAP, TAZ and MST1, 
serve a critical role in invasive breast tumor colonization 
in or outside breast tissue [95]. Relevant data from addi-
tional studies demonstrated that the deficiency of YAP 
decreases the incidence of lung metastasis in a genetically 
engineered breast cancer mouse model. The presence 
of Ski effectively suppresses lung metastasis in breast 
cells following the overexpression of TAZ [96, 97]. The 
Hippo pathway is also necessary for breast cancer, which 
can occur in up to 70% of patients with advanced breast 
cancer. Phosphorylated HER3 Tyr1307 is able to induce 
MST1 methylation at the lys59 site, thereby produc-
ing active YAP/TAZ in tumor cells, thereby promoting 
metastasis in bone cancer [98]. Bartucci et  al. observed 
that the nuclear expression of TAZ in bone metastasis 
was significantly higher than its cytoplasmic expression 
in primary tumors. In addition, a hypoxic microenvi-
ronment in bone marrow is also an important cause of 
tumor infiltration. The hypoxic state is characterized 
by the presence of hypoxic-inducing factor (HIF)-1α. 
Bendinelli et  al. reported that HIF-1α is able to stimu-
late bone metastasis in breast cancer by interacting with 
TAZ in a hypoxic microenvironment [99, 100]. Nuclear 
HIF-1α has been identified to be largely associated with 
EMT in breast cancer metastasis, and can also be regu-
lated by the interaction between E-cadherin and Hippo 
pathway factors [101]. Of note, MST1/2 and LATS1/2, 
the upstream kinases of the Hippo pathway, can regulate 
YAP phosphorylation as tumor suppressors. Therefore, 
LATS1/2 may be a novel target for anticancer treatment 
in breast cancer [94].
Gastric cancer
The high expression of YAP1 in the cytoplasm and 
nucleus has been observed in dysplasia, gastric 
adenocarcinoma and metastatic stomach disease [102]. 
The activation of YAP1 is associated with the poor out-
come of early stage GC. As YAP1 has an upward adjust-
ment ability in GC, siRNA-mediated YAP1 knockdown 
has exhibited inhibitory phonological types, includ-
ing reduced cell proliferation, inhibition of single-layer 
colony formation associated with anchorage, and the 
reduction of cell invasion and migration. In MKN45 cells 
with negative YAP1 expression, the ectopic expression of 
YAP1 promotes anchorage dependence or independent 
colony formation. The ascension of YAP1 in MKN45 cells 
has also led to more invasive phenotypic changes that 
can promote the proliferation of cells in vitro and in vivo 
[103]. YAP1 was further demonstrated to enhance the 
expression of C-fos induced by serum/EGF in GC cells 
[104]. The expression of YAP1 in GC was positively cor-
related with survival [105]. The interaction of YAP1 and 
RUNX2 increases oncogenic transformation by repres-
sion of p21 protein expression [106]. In gastric and lung 
adenocarcinoma, tyrosine kinase AXL is the direct func-
tional target of YAP1 [107]. Several study groups also 
provided a comprehensive account of the similar carcino-
genic effects of YAP1 in the occurrence and metastasis of 
GC [108].
TAZ, another key effector of the Hippo pathway, is 
associated with the abnormal excessive expression of 
β-catenin, which is associated with a poor prognosis in 
patients with esophageal and gastric junction adenocar-
cinoma. The YAP1/TAZ hyperactivation appears to drive 
tumorigenesis in gastrointestinal cancers, and take over 
carcinogenesis in a RAS-independent manner [109].
Hepatocellular cancer
The overexpression of MST1/2 inhibits cell proliferation 
and the mRNA expression of CTGF, AREG and Survivin, 
and promotes YAP1 phosphorylation in the development 
of HCC [110]. Silencing YAP1 can restore hepatocyte dif-
ferentiation by siRNA-lipid nanoparticles (siRNA-LNPs) 
in advanced HCC, and leads to tumor regression [111]. 
The activation of YAP1 is an early event of HCC and is 
an independent prognostic factor [112]. The PDZ bind-
ing motif in YAP1 is crucial for activating the cell pro-
liferation gene CTGF, which is also a TEAD-dependent 
transcription target [113]. CREB (cyclic adenosine 
monophosphate response element-binding protein) pro-
motes the transcriptional output of YAP1 via binding 
to -608/-439 sites, a novel region of the YAP promoter 
[114]. The interaction of MEK1-YAP1 is important in cell 
proliferation and the maintenance of transformed phe-
notype in HCC cells [115]. AMOT-P130 was associated 
with YAP1-TEAD transcription complexes, and helped 
regulate a certain YAP1 targeted genes, which are asso-
ciated with the occurrence of liver tumors [116]. It has 
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been reported that SIRT1 reacts with the YAP1 protein in 
HCC cells, thus activating YAPTU/TEAD4 transcription 
ability and promoting HCC tumor cell growth [117]. In 
conclusion, YAP1 up-regulates Jag-1 in order to activate 
Notch signaling in HCC cells, which indicates that a cor-
relation exists between the Hippo pathway and the carci-
nogenic pathway.
Renal cell carcinoma cancer
It has been detected abnormal Hippo pathway signaling 
in various human cancers can result in hyperactive YAP 
function, including kidney [118]. The nuclear overexpres-
sion of YAP has also been observed in a subset of patients 
with clear cell Renal Cell Carcinoma (ccRCC) [119]. In 
ccRCC tissues and cell lines, YAP mRNA and protein 
expression levels were also observed to be increased. In 
addition, the knockdown of YAP in the 786-0 ccRCC sys-
tem causes cells to stop progressing through the cell cycle 
and an increase in apoptosis [120]. The deletion of the 
Nf2 gene, which can encode the upstream Hippo path-
way regulator Merlin can result in intratubular neoplasia 
that progresses to invasive carcinoma [121]. Of note, in 
this model, early lumen-filling lesions exhibited hyperac-
tive EGFR signaling with EGFR inhibition halting tumor 
cell proliferation. These findings highlight the potentially 
dangerous effects of uncontrolled YAP signals and fur-
ther confirm the cross-dialogue between the Hippo and 
EGFR pathways [122].
Colorectal cancer
In CRC, the study of Liang et al. reported a decrease in 
the mRNA ratio of LATS1 and MST1/2, and an increase 
in mRNA levels in YAP, TAZ, TEAD and OCT4 when 
compared with healthy colon samples [123]. The majority 
of genes that encode Hippo pathway proteins have been 
demonstrated to exert functions as tumor suppressor 
or oncogenes in numerous types of cancer. Wang et  al. 
demonstrated that there was a relationship between the 
expression levels of YAP1 and TAZ and lymph node sta-
tus in CRC [124]. Other reports have stated the prognos-
tic value of the transcriptional levels of YAP1 and TAZ 
for patients with CRC. In 522 cases of CRC the mRNA 
expression rates of TAZ and YAP1 mRNA were positively 
correlated with their downstream targeted genes AXL 
and CTGF [125]. In a quantitative PCR study based on 
the expression of all Hippo pathway elements in CRC, 
the mRNA levels of MST1 and LATS2 in CRC tissues 
decreased more than those in colorectal cancer adeno-
mas or adjacent non-tumor tissues [126]. The increase of 
YAP was also observed in human CRC liver metastases, 
and was correlated with CRC relapse [126].
Hippo pathway in leukemia
YAP acts as an oncoprotein
YAP can interact with TEAD and form a protein com-
plex termed an oncoprotein, which contributed to the 
transcription of target downstream genes, including 
c-Myc and Survivin [127]. It has recently been revealed 
that porphyrin family members including VP, hemato-
porphyrin, and protoporphyrin IX can delete the inter-
actions between YAP and TEAD [128]. In addition, 
subsequent research was performed in chronic mye-
loid leukemia (CML) samples in order to analyze the 
expression of MST1/2 and YAP1. The results revealed 
that the inhibition of YAP results in a marked anti-
tumor effect in CML [129], and the inhibitory effect of 
shRNA and VP on YAP function in HL-60 cells was also 
reported. Also, the study clearly revealed that silencing 
of YAP may serve as a potential treatment strategy for 
acute pro-myelocytic leukemia (APL) [130]. However, 
further investigations are required in order to assess its 
suitability in a clinical setting.
YAP acts as an anti‑cancer protein
Recent data has indicated that YAP1 is stably up-
regulated in epithelial tumor cell lines; however, the 
expression ofYAP1 is markedly reduced in malignant 
hematologic tumors, including lymphoma, leukemia 
and multiple myeloma (MM) [131]. Other reports have 
demonstrated that YAP1 is located in chromosome 
11 at site 11q22.1, and there is a missing of the focal 
homozygous of the site in 5–13% of MM samples [132]. 
BIRC2 and BIRC3, are the primary targets of this dele-
tion, and have been reported to control the pro-onco-
genic NF-κB pathway [133]. In addition, Cottini et  al. 
reported that YAP1was deleted in all examined MM 
cell lines and the majority of MM samples. Importantly, 
the survival rate of low expression of YAP1 in MM sam-
ples was significantly lower than that of higher expres-
sion rate. Additionally, various datasets have reported 
that the knockdown in YAP1 expression levels can pro-
gress from normal plasma cells to MM [131].
Hippo pathway in sarcoma
Osteosarcoma
In osteosarcoma (OS), a report of Chai et  al. showed 
TEAD1 was the major transcription factor of Hippo 
signaling pathway [134]. Knockdown of TEAD1 sup-
pressed multiple malignant phenotypes of OS, such 
as cell proliferation, apoptosis resistance and invasive 
potential through regulation of PTGS2 and CRY61 
[134]. YAP1 is highly expressed and predicts a poor 
prognosis. Silencing of YAP1 may inhibit OS cells 
growth and metastasis [135]. Besides YAP1, TAZ has 
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also been reported be responsible for the progression 
of OS [136].
Rhabdomyosarcoma
YAP has recently been identified as a potent driver of 
embryonal rhabdomyosarcoma (ERMS). Constitutive 
YAP hyperexpression in activated muscle stem cells 
causes ERMS-like tumors [137]. In contrast to YAP, TAZ 
was reported to promote myogenic differentiation, which 
would be anti-tumorigenic [138]. However, Mohamed 
et  al. demonstrated TAZ functions as an oncogene in 
ERMS. TAZ drives expression of ERMS stem cell factor 
Myf5, and promote proliferation of ERMS cells [139]. 
Therefore, more researches need to carry out to confirm 
whether TAZ is an oncogene or suppressor in ERMS.
Angiosarcoma
Human angiosarcoma is a rare malignant vascular tumor 
associated with extremely poor clinical outcome and gen-
erally arising in skin of the head and neck region. Recent 
research demonstrated YAP is specifically expressed and 
translocated in the nucleus in angiosarcomas; and is a key 
modulator of proliferation in human angiosarcomas and 
inhibition of survivin activity may be a potential thera-
peutic target [140].
Current drugs targeting the hippo pathway for cancer 
treatment
With the ever-greater understanding of cellular sign-
aling mechanisms and genetic alterations in carcino-
genesis, considerable progress in cancer treatment has 
been made in recent years. A great number of targeted 
drugs has been identified to improve survival rate of can-
cer patients, such as ibrutinib (BTK inhibitor), idelaisib 
(PI3Kδ inhibitor), and ciclesonide (Smo inhibitor). As 
we mentioned before, hippo pathway is a major signaling 
pathway in the human body, and is responsible for cancer 
development. Therefore, it is important to study hippo 
pathway-targeted drugs to promote cancer-treatment 
methods. In our review, we summarized several hippo 
pathway-targeted drugs (Fig. 6).
MST and LATS activation
F-actin is the inhibitor of MST/LATS, thereby negative 
regulators of F-actin can indirectly activate MST/LATS 
activity. The marine-derived macrolides latrunculin are 
known to disrupt F-actin polymerization. Konishi et  al. 
reported latrunculinA has a strong anti-cancer effect in a 
peritoneal dissemination model of human gastric cancer 
in mice [141]. Besides, Y27632 could activate MST/LATS 
via inhibiting Rho-associated, coiled–coil containing pro-
tein kinase (ROCK). Leonel et al. demonstrated Y27632 
Fig. 6 Hippo pathway-targeted inhibitors. Current Hippo pathway-targeted drugs have been discussed in the review, as shown in the figure
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can inhibit Epithelial-mesenchymal Transition (EMT) of 
breast cancer cell lines [142].
Additionally, a new study showed that IKBKE directly 
targets LATS1/2 and induces degradation of LATS1/2, 
thereby inhibiting the activity of the Hippo pathway 
[143]. Amlexanox, a selective inhibitor of IKBKE, could 
be a potential LATS1/2-target drug [143]. ILK (integ-
rin-linked kinase) is a critical negative regulator of the 
Hippo tumor suppressor pathway, which can prevent 
Merlin dephosphorylation and activation by suppressing 
MYPT1, resulting in the nuclear accumulation of YAP/
TAZ [144]. QLT0267, an inhibitor of ILK, reduces breast 
cancer cell growth by activating MST [144].
Targeting YAP/TAZ regulators
Decursin is a major compound isolated from the root 
of the Korean Dang-Gui. Recent research indicated that 
Decursin shows anti-cancer therapy sensitization. Li 
et al. reported Decursin enables inhibition of YAP activi-
ties that functions by the upregulation of LATS1 phos-
phorylation and ubiquitin E3 ligase, βTRCP in HepG2 
hepatocellular carcinoma cells [145]. Cucurbitacins are 
natural tetracyclic triterpene compounds extracted from 
several plant families such as Cruciferae and Cucurbita-
ceae. These compounds have a broad spectrum of phar-
macological activities including antioxidant, anticancer, 
and antidiabetic. Chai et  al. reported Cucurbitacin B 
exerts anticancer activities in colorectal cancer cells by 
inhibiting YAP protein [146].
Apigenin is a widely distributed flavonoid in vegeta-
bles and fruits. Recent studies have showed that Apigenin 
has anti-cancer activity. Li et al. indicated that Apigenin 
decreased YAP/TAZ activity and the expression of tar-
get genes, such as CTGF and CYR61 in TNBC cells. 
Apigenin is a promising therapeutic agent for the treat-
ment of TNBC patients by inhibiting YAP/TAZ activity 
[147]. Curcumin, a hydrophobic polyphenol derived from 
turmeric (Curcuma Longa), is one of the most-studied 
plant-derived natural products. Curcumin has shown 
anti-proliferation, apoptosis induction and anti-invasion 
in various human cancers. Gao et al. demonstrated Cur-
cumin could down-regulate the expression of YAP/TAZ 
to suppress bladder cancer development, which sug-
gested the therapeutic potential of Curcumin in the treat-
ment of bladder cancer [148].
Inhibition of YAP/TAZ‑TEAD interaction
According to preceding investigation, Verteporfin 
(VP), a YAP specific inhibitor, can block the interac-
tion between YAP and TEAD to repress YAP’s function 
[149]. Several researchers discovered the VP is able to 
restrain cancer cell growth in some tumors, such as ret-
inoblastoma, endometrial and ovarian cancers. Besides 
VP, the other members of the porphyrin family, such as 
hematoporphyrin and protoporphyrin IX are both cur-
rently identified as disruptors of YAP-TEAD interac-
tion in xenograft mouse models [150], which could be 
the next candidates for cancer treatment. In addition, 
Jia et al. reported XAV-939, a Tankyrase inhibitor, can 
decrease YAP protein levels and inhibit YAP-TEAD 
luciferase reporter activity [151].
Conclusion
Taken together, the Hippo pathway plays an essential 
role in most of cancers, which makes it to be a critical 
field for further investigation. From the data described, 
the hippo pathway is the opportunities and challenges 
to the treatment of cancer. A large number of solid 
cancers showed higher-expression of YAP and TAZ, 
knockdown or silencing them will be responsible for 
cancer treatment. However, based on the perspectives 
by research, YAP can be an oncoprotein or anti-tumor 
molecular in malignant hematologic tumors. Other 
core components of Hippo pathway such as LATS1/2 
also are critical for cancer therapy as negative effectors. 
Notably, Hippo pathway is regulated by a complex net-
work of signaling pathway, and microRNAs, circRNAs, 
as well as zinc-finger proteins. Hippo pathway-targeted 
drugs have been identified to treat cancer. Despite 
tremendous researches on Hippo pathway have been 
reported, further knowledge upon it remains unknown 
and needs to be exported.
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